ACU Stock Surges 17.5% on Q2 Earnings Beat Driven by MyMedic Acquisition

• Acme United reported a 50.62% EPS beat in Q2 2026, with earnings reaching $1.22 versus a $0.81 forecast .
• Revenue surged 7.99% to $62.7 million, aided by a 16% YoY sales increase from the MyMedic acquisition .
• Gross margins expanded to 42.6%, up from 41.0% in the prior year period, indicating improved operational efficiency .
• Management anticipates continued margin recovery as higher-tariff inventory is replaced by lower-cost stock .

Acme United Corporation delivered robust second-quarter 2026 financial results, significantly outperforming Wall Street expectations. The company reported earnings per share of $1.22, surpassing the consensus forecast of $0.81 by a wide margin. This 50.62% surprise was primarily fueled by a 16% year-over-year increase in sales. The top-line growth was largely attributed to the recent acquisition of MyMedic, which provided a substantial boost to revenue figures. Excluding the acquisition, the company still achieved an 8% increase in organic sales. The stock market reacted swiftly to the positive news, with shares surging 17.52% following the earnings release. The price movement brought the stock close to its 52-week high of $51.88, reflecting strong investor confidence in the company's immediate prospects.

How Did MyMedic Acquisition Impact Financial Performance?

The acquisition of MyMedic has played a pivotal role in Acme United's recent financial outperformance. The integration of this asset has not only accelerated top-line growth but also provided a catalyst for margin expansion. Gross margins improved to 42.6% from 41.0% in the same quarter last year. This expansion suggests that the company is successfully leveraging pricing power and operational efficiencies. EBITDA also saw a dramatic increase, growing by 136.13% to reach $8.777 million. The EBITDA margin stood at approximately 14%, highlighting the improved profitability of the business model. Management is actively working to expand MyMedic's distribution beyond its current direct-to-consumer channels. The strategic goal is to penetrate mass retail markets, which could further drive long-term revenue growth. However, the company is also navigating elevated selling, general, and administrative expenses, which remain at 32% of sales. This high expense ratio poses a potential constraint on near-term margin expansion despite the strong revenue performance.

What Are the Key Risks and Forward-Looking Outlook?

Despite the strong quarterly results, several headwinds remain for Acme United. The company faces ongoing challenges from tariff costs, freight expenses, and currency fluctuations. CEO Johnsen has indicated that gross margin recovery is expected to continue as the company transitions its inventory mix. Higher-tariff stock is being systematically replaced by lower-cost inventory, a process management expects to complete by the end of the year. Geographic performance has been uneven, with Canada lagging behind other regions. This disparity adds complexity to the company's global operational strategy. Looking ahead, management forecasts strong profitability in the fourth quarter, supported by seasonal demand patterns. However, analysts note that SG&A expenses remain a significant drag on profitability. The company's beta of 0.43 suggests lower volatility compared to the broader market, but the elevated expense structure requires careful monitoring.

How Do Analyst Forecasts and Technical Indicators Compare?

Analyst sentiment and technical indicators present a mixed picture for Acme United. A single Wall Street analyst from Freedom Capital Markets maintains a Buy rating with a 12-month price target of $58.00. This target implies a potential downside of approximately 15.95% from the current trading level of $63.06. In contrast, long-term historical seasonality data spanning 53 years indicates a more bullish outlook. The data shows that ACU has risen in 30 of those years over the subsequent 52-week period. Based on this historical accuracy, a model forecasts a rise to $71.10 over the next 52 weeks. Technical analysis also shows a strong bullish trend, with the share price remaining above its 5, 20, and 50-day exponential moving averages. However, the stock is experiencing slight selling pressure in the short term. An AI model-generated price target suggests a 6-month target of $61.44, implying a modest 2.6% downside. This forecast integrates financial fundamentals with alternative data signals, including hiring trends and employee sentiment. The divergence between short-term technical selling and long-term historical patterns highlights the complexity of forecasting the stock's trajectory.

The company operates in the Health Care Equipment & Supplies sector with a market capitalization of approximately $260.6 million. Earnings estimates suggest an increase of $0.21 per share for the current quarter and $0.23 for the full year. However, a decrease of $0.81 is projected for the next year, indicating potential challenges in sustaining the current growth rate. Investors should weigh the strong Q2 performance against these longer-term projections and the various operational headwinds. The successful integration of MyMedic and the execution of the inventory transition will be critical factors in determining the company's future success.